|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis C in hemodialysis patients显示文摘Despite reduction of hepatitis C prevalence after recognition of the virus and testing of blood products, hemodialysis(HD) patients still comprise a high risk group. The natural history of hepatitis C virus(HCV) infection in dialysis is not fully understood while the clinical outcome differs from that of the general population. HD patients show a milder liver disease with lower aminotransferase and viral levels depicted bymilder histological features on liver biopsy. Furthermore, the 'silent' clinical course is consistent with a slower disease progression and a lower frequency of cirrhosis and hepatocellular carcinoma. Potential explanations for the 'beneficial' impact of uremia and hemodialysis on chronic HCV infection are impaired immunosurveillance leading to a less aggressive host response to the virus and intradialytic release of 'hepatoprotective' cytokines such as interferon(IFN)-α and hepatocyte growth factor. However, chronic hepatitis C is associated with a higher liver disease related cardiovascular and allcause mortality of HD patients. Therapy is indicated in selected patients groups including younger patients with low comorbidity burden and especially renal transplant candidates, preferably after performance of a liver biopsy. According to current recommendations, choice of treatment is IFN or pegylated interferon with a reported sustained viral response at 30%-40% and a withdrawal rate ranging from 17% to 30%. New data regarding combination therapy with low doses of ribavirin which provide higher standard variable rates and good safety results, offer another therapeutic option. The new protease inhibitors may be the future for HCV infected HD patients, though data are still lacking. | Smaragdi Marinaki John N Boletis Stratigoula Sakellariou Ioanna K Delladetsima | 2015 | World Journal of Hepatology2015，7，3： | 2 |
| 2 | CT in appendicictis显示文摘 | Athanasios N Chalazoniti S Ioanna T | 2008 | Diagnostic and Interventional Radiology2008，13，1： | 1 |
| 3 | CO2 capture by a task-specific ionic liquid显示文摘 | REBECCA D M IOANNA N | 2002 | J Am Chem Soc2002，124，6： | 1 |
| 4 | CT in appendicictis显示文摘 | Athanasios N Chalazoniti S Ioanna T | 2008 | Diagnostic and Interventianal Radiology2008，13，1： | 1 |
| 5 | CO2 capture by a task-specific lonic liquid显示文摘 | Eleanor D B Rebecca D M Ioanna N | | 0，，06： | 1 |
| 6 | Novel Brgnsted acidic ionic liquids and their use as dual solvent-catalysts 显示文摘 | Amanda C C Jessica L J Ioanna N | 2002 | J Am Chem Soc2002，124，21： | 1 |
| 7 | Novel Bronsted acidic ionic liquids and their Use as dual solvent-catalysts显示文摘 | Cole A C Jessica L Ioanna N | 2002 | J Am Chem Soc2002，124，： | 1 |
| 8 | Novel Brnsted acidic ionic liquids and their use as dual solvent-catalysts 显示文摘 | Amanda C C Jessica L J Ioanna N | 2002 | J Am Chem Soc2002，124，21： | 1 |
| 9 | CO2 Capture by atask-specific ionic liquid显示文摘 | Eleanor D B Rebecca D M Ioanna N | 2002 | Journal of the American ChemicalSociety2002，124，： | 1 |
| 10 | Hyperglycaemia in acute ischaemic stroke is associated with an increased 5- year mortality显示文摘 | Kolaos N Ioanna M Helen C | 2009 | Age and Ageing2009，38，： | 1 |
| 11 | Novel Bronsted acidic ionic liquids and their use as dual solvent- catalysts显示文摘 | Amanda C C Jessica L J Ioanna N | 2002 | J Am Chem Soc2002，124，21： | 1 |
| 12 | Hepatitis B in renal transplant patients显示文摘Hepatitis B virus(HBV) poses a significant challenge for both dialysis patients and kidney transplant recipients despite its decreasing rates, especially in developed countries. The best preventive method is vaccination. Patients with chronic renal disease should ideally be vaccinated prior to dialysis, otherwise, reinforced vaccination practices and close antibody titer monitoring should be applied while on dialysis. HBV infected dialysis patients who are renal transplant candidates must be thoroughly examined by HBV-DNA, and liver enzyme testing and by liver biopsy. When needed, one must consider treating patients with tenofovir or entecavir rather than lamivudine. Depending on the cirrhosis stage, dialysis patients are eligible transplant recipients for either a combined kidney-liver procedure in the case of decompensated cirrhosis or a lone kidney transplantation since even compensated cirrhosis after sustained viral responders is no longer considered an absolute contraindication. Nucleoside analogues have led to improved transplantation outcomes with both long-term patient and graft survival rates nearing those of HBs Ag(-) recipients. Moreover, in the cases of immunized HBs Ag(-) potential recipients with concurrent prophylaxis, we are enabled today to safely use renal grafts from both HBs Ag(+) and HBs Ag(-)/antiHBc(+) donors. In so doing, we avoid unnecessary organ discarding. Universal prophylaxis with entecavir is recommended in HBV kidney recipients and should start perioperatively. One of the most important issues in HBV(+) kidney transplantation is the duration of antiviral prophylaxis. In the absence of robust data, it seems that prophylactic treatment may be discontinued in selected stable, low-risk recipients during maintenance immunosuppression and should be reintroduced when the immune status is altered. All immunosuppressive agents in kidney transplantation can be used in HBV(+) recipients. Immunosuppression is intimately associated with increased viral replication; thus it is important to minimize the total immunosuppression burden long term. | Smaragdi Marinaki Kyriaki Kolovou Stratigoula Sakellariou John N Boletis Ioanna K Delladetsima | 2017 | World Journal of Hepatology2017，9，25： | 0 |
| 13 | Role of vitamin D in cystic fibrosis and non-cystic fibrosis bronchiectasis显示文摘Bronchiectasis is usually classified as cystic fibrosis(CF) related or CF unrelated(non-CF); the latter is not considered an orphan disease any more, even in developed countries. Irrespective of the underlying etiology, bronchiectasis is the result of interaction between host, pathogens, and environment. Vitamin D is known to be involved in a wide spectrum of significant immunomodulatory effects such as down-regulation of pro-inflammatory cytokines and chemokines. Respiratory epithelial cells constitutively express 1α-hydroxylase leading to the local transformation of the inactive 25(OH)-vitamin D to the active 1,25(OH)_2-vitamin D. The latter through its autocrine and paracrine functions up-regulates vitamin D dependent genes with important consequences in the local immunity of lungs. Despite the scarcity of direct evidence on the involvement of vitamin D deficiency states in the development of bronchiectasis in either CF or non-CF patients, it is reasonable to postulate that vitamin D may play some role in the pathogenesis of lung diseases and especially bronchiectasis. The potential contribution of vitamin D deficiency in the process of bronchiectasis is of particular clinical importance, taking into consideration the increasing prevalence of vitamin D deficiency worldwide and the significant morbidity of bronchiectasis. Given the well-established association of vitamin D deficiency with increased inflammation, and the indicative evidence for harmful consequences in lungs, it is intriguing to speculate that the administration of vitamin D supplementation could be a reasonable and cost effective supplementary therapeutic approach for children with non-CF bronchiectasis. Regarding CF patients, maybe in the future as more data become available, we have to re-evaluate our policy on the most appropriate dosage scheme for vitamin D. | Maria Moustaki Ioanna Loukou Kostas N Priftis Konstantinos Douros | 2017 | World Journal of Clinical Pediatrics2017，6，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员